Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy, chemoradiation and consolidation chemotherapy before surgery in high-risk rectal cancer
2020-002727-11Phase 2Active
- Sponsor
- Centro di Riferimento Oncologico di Aviano
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in rectal adenocarcinoma and rectal cancer, sponsored by Centro di Riferimento Oncologico di Aviano. Primary endpoint: Complete pathological remission rate (pCR). Started Jan 2022; status: active.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2020-002727-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002727-11.